PT  - JOURNAL ARTICLE
AU  - Tim K. Mackey
AU  - Bryan A. Liang
TI  - Physician Payment Disclosure Under Health Care Reform: Will the Sun Shine?
AID  - 10.3122/jabfm.2013.03.120264
DP  - 2013 May 01
TA  - The Journal of the American Board of Family
                Medicine
PG  - 327--331
VI  - 26
IP  - 3
4099  - http://www.jabfm.org/content/26/3/327.short
4100  - http://www.jabfm.org/content/26/3/327.full
SO  - J Am Board Fam Med2013 May 01; 26
AB  - Pharmaceutical marketing has become a mainstay in U.S. health care delivery and traditionally has been directed toward physicians. In an attempt to address potential undue influence of industry and conflicts of interest that arise, states and the recently upheld health care reform act have passed transparency, or “sunshine,” laws requiring disclosure of industry payments to physicians. The Centers for Medicare & Medicaid Services recently announced the final rule for the Sunshine Provisions as part of the reform act. However, the future effectiveness of these provisions are questionable and may be limited given the changing landscape of pharmaceutical marketing away from physician detailing to other forms of promotion. To address this changing paradigm, more proactive policy solutions will be necessary to ensure adequate and ethical regulation of pharmaceutical promotion.